| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.
|
Leukemia
|
2003
|
3.89
|
|
2
|
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
|
Leukemia
|
2003
|
2.89
|
|
3
|
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
|
Leukemia
|
2008
|
1.79
|
|
4
|
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
|
Leukemia
|
2003
|
1.56
|
|
5
|
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
|
Leukemia
|
2011
|
1.45
|
|
6
|
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.
|
Leukemia
|
2008
|
1.27
|
|
7
|
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
|
Leukemia
|
2006
|
1.12
|
|
8
|
Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs.
|
Leukemia
|
1999
|
1.09
|
|
9
|
Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.
|
Clin Cancer Res
|
2001
|
1.06
|
|
10
|
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
|
Leukemia
|
2008
|
1.05
|
|
11
|
Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism.
|
Blood
|
1991
|
1.05
|
|
12
|
A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.
|
Oncogene
|
2000
|
0.98
|
|
13
|
Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
|
Cancer Detect Prev
|
2001
|
0.92
|
|
14
|
The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors.
|
Pharmacol Ther
|
2000
|
0.89
|
|
15
|
Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells.
|
Leukemia
|
2000
|
0.87
|
|
16
|
Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.
|
Leukemia
|
2000
|
0.86
|
|
17
|
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
|
Leukemia
|
2003
|
0.86
|
|
18
|
Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells.
|
Leukemia
|
1998
|
0.85
|
|
19
|
Regulation of the interleukin-3 (IL-3) receptor by IL-3 in the fetal liver-derived FL5.12 cell line.
|
Blood
|
1994
|
0.83
|
|
20
|
Autocrine transformation of human hematopoietic cells after transfection with an activated granulocyte/macrophage colony stimulating factor gene.
|
Cytokines Cell Mol Ther
|
1997
|
0.82
|
|
21
|
Abnormal activation of cytokine gene expression by intracisternal type A particle transposition: effects of mutations that result in autocrine growth stimulation and malignant transformation.
|
Cytokines Cell Mol Ther
|
1997
|
0.82
|
|
22
|
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
|
Leukemia
|
2001
|
0.80
|
|
23
|
Effects of phorbol esters on an interleukin-3-dependent cell line.
|
Blood
|
1990
|
0.79
|
|
24
|
Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cells.
|
Blood
|
1995
|
0.79
|
|
25
|
Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells.
|
Leukemia
|
2001
|
0.79
|
|
26
|
Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells.
|
Leukemia
|
2000
|
0.78
|
|
27
|
Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf.
|
Adv Enzyme Regul
|
2001
|
0.78
|
|
28
|
Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells.
|
Eur J Immunol
|
1989
|
0.77
|
|
29
|
Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells.
|
Adv Enzyme Regul
|
2000
|
0.76
|
|
30
|
Phorbol esters support the proliferation of a hematopoietic cell line by upregulating c-jun expression.
|
Oncogene
|
1994
|
0.76
|
|
31
|
Differential effect of phorbol esters and interleukin-3 on protein kinase C isoform content and kinase activity in the FDC-P1 cell line.
|
Blood
|
1991
|
0.76
|
|
32
|
Retroviral infection can abrogate the factor-dependency of hematopoietic cells by autocrine and non-autocrine mechanisms depending on the presence of a functional viral oncogene.
|
Oncogene
|
1993
|
0.76
|
|
33
|
Interleukin-3 and phorbol esters induce different patterns of immediate-early gene expression in an interleukin-3 dependent cell line.
|
Oncogene Res
|
1991
|
0.75
|
|
34
|
Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells.
|
Leukemia
|
2001
|
0.75
|
|
35
|
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
|
Leukemia
|
2003
|
0.75
|